182 related articles for article (PubMed ID: 20145213)
1. BRAF inhibitors: research accelerates in wake of positive findings.
Brower V
J Natl Cancer Inst; 2010 Feb; 102(4):214-5. PubMed ID: 20145213
[No Abstract] [Full Text] [Related]
2. Is it good or bad to find a BRAF mutation?
Flaherty KT
J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
[No Abstract] [Full Text] [Related]
3. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
4. Targeting metastatic melanoma.
Flaherty KT
Annu Rev Med; 2012; 63():171-83. PubMed ID: 22034865
[TBL] [Abstract][Full Text] [Related]
5. [Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma].
Schadendorf D
J Dtsch Dermatol Ges; 2011 Apr; 9(4):340. PubMed ID: 21439018
[No Abstract] [Full Text] [Related]
6. A new standard of care for metastatic melanoma?
Sharma SP
Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
[No Abstract] [Full Text] [Related]
7. Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.
Sondak VK; Smalley K
Pigment Cell Melanoma Res; 2009 Aug; 22(4):386-7. PubMed ID: 19624312
[No Abstract] [Full Text] [Related]
8. [BRAF mutation testing for the choice of melanoma treatment].
Imianitov EN
Arkh Patol; 2012; 74(5):65-71. PubMed ID: 23342664
[TBL] [Abstract][Full Text] [Related]
9. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
10. Cancer research. Melanoma drug vindicates targeted approach.
Garber K
Science; 2009 Dec; 326(5960):1619. PubMed ID: 20019269
[No Abstract] [Full Text] [Related]
11. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.
Koers K; Francken AB; Haanen JB; Woerdeman LA; van der Hage JA
J Clin Oncol; 2013 Jun; 31(16):e251-3. PubMed ID: 23569313
[No Abstract] [Full Text] [Related]
12. Selumetinib increases the efficacy of first-line dacarbazine.
Cancer Discov; 2013 Jul; 3(7):OF16. PubMed ID: 23847359
[TBL] [Abstract][Full Text] [Related]
13. The new arms race against melanoma.
Lejeune FJ
Melanoma Res; 2006 Feb; 16(1):1-2. PubMed ID: 16432449
[No Abstract] [Full Text] [Related]
14. Novel inhibitors in the treatment of metastatic melanoma.
Kalinsky K; Haluska FG
Expert Rev Anticancer Ther; 2007 May; 7(5):715-24. PubMed ID: 17492934
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report.
Richtig E; Schrama D; Ugurel S; Fried I; Niederkorn A; Massone C; Becker JC
Br J Dermatol; 2013 Feb; 168(2):428-30. PubMed ID: 22775439
[No Abstract] [Full Text] [Related]
16. [Melanoma and search for therapeutic targets].
de la Fouchardière A
Ann Pathol; 2011 Nov; 31(5 Suppl):S123-4. PubMed ID: 22054449
[No Abstract] [Full Text] [Related]
17. BRAF in melanoma: current strategies and future directions.
Salama AK; Flaherty KT
Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
[TBL] [Abstract][Full Text] [Related]
18. Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors.
Falanga A; Marchetti M; Massi D; Merelli B; Verzeroli C; Russo L; Rulli E; Tondini C; Legramandi L; Nassini R; Scatena C; De Logu F; Cattaneo L; Mandalà M
J Am Acad Dermatol; 2016 Jun; 74(6):1254-1256.e4. PubMed ID: 27185428
[No Abstract] [Full Text] [Related]
19. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
20. Two cases of immune thrombocytopenia associated with pembrolizumab.
Le Roy A; Kempf E; Ackermann F; Routier E; Robert C; Turpin A; Marabelle A; Mateus C; Michot JM; Lambotte O
Eur J Cancer; 2016 Feb; 54():172-174. PubMed ID: 26687374
[No Abstract] [Full Text] [Related]
[Next] [New Search]
